文献速递MDS 与骨髓增殖性肿瘤白血病

ERK2-DBP结构域抑制小鼠JAK2V617F驱动骨髓增殖性肿瘤的发病

The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm.
PubMed 文献 · Blood · 2022-01-01

研究利用JAK2依赖的真性红细胞增多症(PV)小鼠模型,发现ERK2-DBP结构域失活会促进疾病从PV向骨髓纤维化进展,并阻止JAK2V617F诱导的癌基因诱导性衰老。靶向ERK2-D结构域的藥物可减弱JAK2依赖性骨髓增殖性肿瘤细胞系的生长,提示D结构域可能成为Ras/MAPK依赖性癌症的治疗靶点。

要点

  • 小鼠ERK2-DBP结构域失活导致基线红细胞增多。
  • ERK2-DBP失活促进PV向骨髓纤维化进展,提示该结构域通常抑制进展。
  • 靶向ERK2-D结构域的藥物可减弱JAK2依赖性骨髓增殖性肿瘤细胞系生长。

核心结论

  • ERK-D与ERK-DBP结构域在肿瘤进展中可发挥不同作用,D结构域有潜力成为Ras/MAPK依赖性癌症的强效治疗靶点。

研究设计与样本

  • 研究采用JAK2依赖的真性红细胞增多症(PV)小鼠模型,并在体外使用JAK2依赖性骨髓增殖性肿瘤细胞系。

主要发现

  • 小鼠ERK2-DBP结构域失活引起基线红细胞增多。
  • 在JAK2依赖的PV模型中,ERK2-DBP结构域失活促进疾病从PV向骨髓纤维化进展。
  • ERK2-DBP失活阻止JAK2V617F在体外促进癌基因诱导性衰老。
  • ERK2-DBP突变通过阻止ERK2与转录因子Egr1的物理相互作用,减弱JAK2介导的癌基因诱导性衰老。

临床怎么用

  • 作者认为,靶向ERK2-D结构域的药物可能减弱癌细胞生长;靶向ERK2-D结构域的药物在JAK2依赖性骨髓增殖性肿瘤细胞系中有效减弱生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although Ras/mitogen-activated protein kinase (MAPK) signaling is activated in most human cancers, attempts to target this pathway using kinase-active site inhibitors have not typically led to durable clinical benefit. To address this shortcoming, we sought to test the feasibility of an alternative targeting strategy, focused on the ERK2 substrate binding domains, D and DEF binding pocket (DBP). Disabling the ERK2-DBP domain in mice caused baseline erythrocytosis. Consequently, we investigated the role of the ERK2-D and -DBP domains in disease, using a JAK2-dependent model of polycythemia vera (PV). Of note, inactivation of the ERK2-DBP domain promoted the progression of disease from PV to myelofibrosis, suggesting that the ERK2-DBP domain normally opposes progression. ERK2-DBP inactivation also prevented oncogenic JAK2 kinase (JAK2V617F) from promoting oncogene-induced senescence in vitro. The ERK2-DBP mutation attenuated JAK2-mediated oncogene-induced senescence by preventing the physical interaction of ERK2 with the transcription factor Egr1. Because inactivation of the ERK2-DBP created a functional ERK2 kinase limited to binding substrates through its D domain, these data suggested that the D domain substrates were responsible for promoting oncogene-induced progenitor growth and tumor progression and that pharmacologic targeting of the ERK2-D domain may attenuate cancer cell growth. Indeed, pharmacologic agents targeting the ERK2-D domain were effective in attenuating the growth of JAK2-dependent myeloproliferative neoplasm cell lines. Taken together, these data indicate that the ERK-D and -DBP domains can play distinct roles in the progression of neoplasms and that the D domain has the potential to be a potent therapeutic target in Ras/MAPK-dependent cancers.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Truong B, Fahl SP, et al. The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm. Blood. 2022. PMID: 35436326. doi:10.1182/blood.2021013068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。